Bicistronic CAR T-cell therapy can produce durable complete responses in pediatric patients with relapsed or refractory B-ALL, data suggest.

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.

(HealthDay News) — The mean body mass index (BMI) and prevalence of obesity declined in the United States in 2023, according to research published in JAMA Health Forum.

Both dose levels of modakafusp alfa “resulted in good response rates with similar safety profiles,” according to researchers.

This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

Research presented at ASH 2024 could change the treatment of patients with newly diagnosed and relapsed or refractory MM, ...

Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.

The FDA has approved Ensacove (ensartinib) to treat patients with ALK+ advanced NSCLC who have not previously received an ALK inhibitor.

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Life expectancy in the United States is worse than in many other countries and declined from 1990 to 2021, data suggest.

In a phase 3 trial, ASCT did not improve survival outcomes in patients with MCL who had an MRD-negative CR after induction.